Interleukin-10 is an independent biomarker of severe traumatic brain injury prognosis

NeuroImmunoModulation

Volumn 19, Issue 6, 2012, Pages 377-385

  Schneider Soares, Flvia Mahatma ^a   Menezes De Souza, Nicole ^d   Librio Schwarzbold, Marcelo ^a   Paim Diaz, Alexandre ^a   Costa Nunes, Jean ^a   Hohl, Alexandre ^a   Nunes Abreu Da Silva, Priscilla ^a   Vieira, Juliana ^a   Lisboa De Souza, Rafael ^f   Mor Bertotti, Melina ^d   Schoder Prediger, Rui Daniel ^e   Neves Linhares, Marcelo ^a,b,d   Bafica, Andr ^d   Walz, Roger ^a,c  

^a Centro de Neurociências Aplicadas   (Brazil)

^b Departamento de Cirurgia   (Brazil)

^c Hospital Universitario   (Brazil)

^d Laboratrio de Imunofarmacologa e Doenas Infecciosas ^*  (Brazil)

^e FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^f HOSPITAL GOVERNADOR CELSO RAMOS   (Brazil)

Author keywords

Cytokines; IL 10; Prognosis; TNF ; Traumatic brain injury

Indexed keywords

INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GLASGOW COMA SCALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PUPIL REFLEX; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; TRAUMATIC BRAIN INJURY;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BRAIN INJURIES; FEMALE; GLASGOW COMA SCALE; HUMANS; INJURY SEVERITY SCORE; INTERLEUKIN-10; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; UP-REGULATION; YOUNG ADULT;

EID: 84867459480     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000342141     Document Type: Article

References (29)

1. Martins ET, Linhares MN, Sousa DS, et al: Mortality in severe traumatic brain injury: a multivariated analysis of 748 patients from Florianópolis city. J Trauma 2009; 67: 85-90.
2. MRC CRASH Trial Collaborators, Perel P, Arango M, Clayton T, Edwards P, Komolafe E, Poccock S, Roberts I, Shakur H, Steyerberg E, Yutthakasemsunt S: Predicting outcome after traumatic brain injury: practical prognostic models based on large cohort of international patients. BMJ 2008; 336:425-429.
3. Diaz AP, Schwarzbold ML, Thais ME, Hohl A, Bertotti MM, Schmoeller R, Nunes JC, Prediger R, Linhares MN, Guarnieri R, Walz R: Psychiatric disorders and health-related quality of life after severe traumatic brain injury: a prospective study. J Neurotrauma 2012; 29: 1029-1037.
4. Thais ME, Cavallazzi G, Schwarzbold ML, Diaz AP, Ritter C, Petronilho F, Hohl A, Prediger RD, Linhares MN, Pizzol FD, Walz R: Plasma levels of oxidative stress biomarkers and long-term cognitive performance after severe head injury. CNS Neurosci Therap 2012; 18: 606-608.
5. Schwarzbold M, Diaz A, Martins ET, Rufino A, Amante LN, Thais ME, Quevedo J, Hohl A, Linhares MN, Walz R: Psychiatric disorders and traumatic brain injury. Neuropsychiatr Dis Treat 2008; 4: 797-816.
6. Lu J, Goh SJ, Tng PY, et al: Systemic inflammatory response following acute traumatic brain injury. Front Biosci 2009; 14: 3795-3813.
7. Kadhim HJ, Duchateau J, Sebire G: Cytokines and brain injury: invited review. J Intensive Care Med 2008; 23: 236-249.
8. Soriano SG, Piva S: Central nervous system inflammation. Eur J Anaesthesiol Suppl 2008; 42: 154-159.
9. Gullo JS, Bertotti MM, Silva CC, Schwarzbold M, Diaz AP, Soares FM, Freitas FC, Nunes J, Pinheiro JT, Morato EF, Prediger RD, Linhares MN, Walz R: Hospital mortality of patients with severe traumatic brain injury is associated with serum PTX3 levels. Neurocrit Care 2011; 14: 194-199.
10. Schwarzbold ML, Rial D, De Bem T, Machado DG, Cunha MP, dos Santos AA, dos Santos DB, Figueiredo CP, Farina M, Goldfeder EM, Rodrigues AL, Prediger RD, Walz R: Effects of traumatic brain injury of different severities on emotional, cognitive, and oxidative stress-related parameters in mice. J Neurotrauma 2010; 27: 1883-1893.
11. Engelhardt B: Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 2008; 274: 23-26.
12. D'Mello C, Le T, Swain MG: Cerebral microglia recruit monocytes into the brain in response to tumor necrosis factor alpha signaling during peripheral organ inflammation. J Neurosci 2009; 29: 2089-2102.
13. Kirchhoff C, Buhmann S, Bogner V, et al: Cerebrospinal IL10 concentration is elevated in non-survivors as compared to survivors after severe traumatic brain injury. Eur J Med Res 2008; 13: 464-468.
14. Laird MD, Vender JR, Dhandapani KM: Opposing roles for reactive astrocytes following traumatic brain injury. Neurosignals 2008; 16: 154-164.
15. Maas AI, Steyerberg EW, Butcher I, et al: Prognostic value of computerized tomography scan characteristics in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24: 303-314.
16. McHugh GS, Engel DC, Butcher I, et al: Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24: 287-293.
17. Murray GD, Butcher I, McHugh GS, et al: Multivariable prognostic analysis in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24: 329-337.
18. Van Beek JG, Mushkudiani NA, Steyerberg EW, et al: Prognostic value of admission laboratory parameters in traumatic brain injury: results from the IMPACT study. J Neurotrauma 2007; 24: 315-328.
19. Dziurdzik P, Krawczyk L, Jalowiecki P, Kondera-Anasz Z, Menon L: Serum interleukin-
20. in ICU patients with severe acute central nervous system injuries. Inflamm Res 2004; 53: 338-343.
21. Bell MJ, Kochanek PM, Doughty LA, et al: Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J Neurotrauma 1997; 14: 451-457.
22. Marmarou A, Lu J, Butcher I, et al: Prognostic value of the Glasgow Coma Scale and pupil reactivity in traumatic brain injury assessed pre-hospital and on enrollment: an IMPACT analysis. J Neurotrauma 2007; 24: 270-280.
23. Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T: IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF beta1 and blood-brain barrier function. J Neuroimmunol 1999; 101: 211-221.
24. Neidhardt R, Keel M, Steckholzer U, et al: Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma 1997; 42: 863-870.71.
25. Shiozaki T, Hayakata T, Tasaki O, et al: Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock 2005; 23: 406-410.
26. Woiciechowsky C, Asadullah K, Nestler D, et al: Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med 1998; 4: 808-813.
27. Doni A, Michela M, Bottazzi B, Peri G, Valentino S, Polentarutti N, Garlanda C, Mantovani A: Regulation of PTX3, a key component of humoral innate immunity in human dendritic cells: stimulation by IL-10 and inhibition by IFN-gamma. J Leukoc Biol 2006; 79: 797-802.
28. Sharma S, Yang B, Xi X, Grotta JC, Aronowski J, Savitz SI: IL-10 directly protects cortical neurons by activating PI-3 kinase and STAT-3 pathways. Brain Res 2011; 1373: 189-194.
29. Knoblach SM, Faden AI: Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 1998; 153: 143-151.